Fludarabine and mitoxantrone for the refractory relapse treatment of B-cell low-grade non-Hodgkin lymphoma (NHL):: LACOHG first interim report (Latin American Cooperative Oncology Hematology Group).

被引：0
|
作者：
Baltazar-Arellano, Severiano
Pimentel, Patricia
Vera, Luis
Bezares, Fernando
Malaga, Jose
Huamani-Z, Julia
Montante, Antonio
Rivas-Vera, Silvia
Carrasco-Yalan, Antonio A.
Beltran-Garate, Brady E.
机构：
[1] Ctr Med Noreste, Monterrey, Mexico
[2] Hosp Edgardo Rebagliati Martins, Dept Hematol Oncol, Lima, Peru
[3] Hosp Alvarez, Dept Hematol, Buenos Aires, DF, Argentina
[4] Hosp Natl Del Sur, Dept Hematol, Arequipa, Peru
[5] Hosp Gen Mexico OD, Mexico City, DF, Mexico
[6] Inst Nacl Cancerol, Mexico City, DF, Mexico
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4665
引用
收藏
页码：247B / 248B
页数：2
相关论文
共 50 条
  • [11] Chest Wall Mass as the Dominant Presentation of Low-Grade B-Cell Non-Hodgkin's Lymphoma: A Case Report
    Sonavane, Sunita Nitin
    Basu, Sandip
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2022, 21 (02) : 169 - 172
  • [12] Fludarabine, mitoxantrone and dexamethasone for the first line treatment of patients with indolent non-Hodgkin lymphoma (NHL): GATLA first interim report (Grupo Argentino de Tratamiento de la Leucemia Aguda).
    Milone, Gustavo
    Rodriguez, A.
    Milone, Jorge
    Bezares, R. F.
    Rudoy, S.
    Palmer, Luis
    Cerruti, I.
    Lastiri, Francisco
    BLOOD, 2006, 108 (11) : 252B - 252B
  • [13] A randomized trial of fludarabine, mitoxantrone (FM) versus doxorubicin, cyclophosphamide, vindesine, prednisone (CHEP) as first line treatment in patients with advanced low-grade non-Hodgkin lymphoma (LG-NHL): A multicenter study by Goelams Group
    Foussard, C
    Deconinck, E
    Desablens, B
    Ghandouri, C
    Milpied, N
    Vilque, JP
    Dugay, J
    Delwail, V
    Jaubert, J
    Escoffre, M
    Maisonneuve, H
    Gressin, R
    Le Maignan, C
    Colombat, P
    BLOOD, 1998, 92 (10) : 316A - 316A
  • [14] An Unusual Presentation of Supraglottic Low-Grade B-Cell Non-Hodgkin's Lymphoma with Tracheostomal Myiasis
    Mehta, Rupa
    Sasanka, Krishna K. S. B. S.
    Ravina, Mudalsha
    Nagarkar, Nitin M.
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2022, 37 (02): : 196 - 198
  • [15] Comparitive economic analysis of the treatment of relapsed low grade B cell non-Hodgkin's lymphoma (NHL) using CHOP, fludarabine or rituximab.
    Sweetenham, J
    McIntyre, AM
    Howard, P
    Smartt, P
    Kerrigan, M
    Townshend, S
    Hieke, K
    BLOOD, 1998, 92 (10) : 415A - 415A
  • [16] Randomized phase II evaluation of fludarabine (RdA) and 2-chloredeossiadenosine (CdA) in the treatment of relapsed/refractory low-grade non-Hodgkin's lymphoma (NHL) and CLL.
    Tondini, C
    Balzarotti, M
    Rampinelli, I
    Luoni, M
    DePaoli, A
    Valagussa, P
    Santoro, A
    Bajetta, E
    Bonadonna, G
    Bregni, M
    BLOOD, 1997, 90 (10) : 1532 - 1532
  • [17] Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma
    Howe, D
    Bromidge, T
    LEUKEMIA RESEARCH, 2006, 30 (01) : 29 - 32
  • [18] A Rare Case of Low-Grade B-cell Non-Hodgkin's Lymphoma of the Lower Lip Mimicking a Mucocele
    Jayabalan, Jones
    Albert, Dyna
    Nathanael, Israel
    Abisheg, Jedidiah Fredrick
    Balakrishna, R. N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [19] Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia
    Foran, JM
    Oscier, D
    Orchard, J
    Johnson, SA
    Tighe, M
    Cullen, MH
    de Takats, PG
    Kraus, C
    Klein, M
    Lister, TA
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1574 - 1579
  • [20] When and what is the ideal first-line therapy for low-grade B-cell non-Hodgkin lymphomas?
    Karakatsanis, S.
    Karmiris, T.
    ARCHIVES OF HELLENIC MEDICINE, 2013, 30 (03): : 289 - 298
12345